CytoDyn's Phase 2 study in mCRC (NCT06699836), now underway, is enrolling 60 participants who will be tested with the LifeTracDx ® blood test at multiple-time points over the course of the trial.

The MarketWatch News Department was not involved in the creation of this content. MONMOUTH JUNCTION, N.J., March 3, 2026 /PRNewswire/ -- Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv") has ...

INDIANAPOLIS -- The NFL Scouting Combine is in the books, and what a week it was. With the final group of prospects now having completed measurements and on-field workouts, another year in ...

The Bitcoin Quantum testnet provides developers, miners, and researchers with a live environment to evaluate how ...

It's a striking statement in a field long defined by binders, screenshots, and scripted test runs meant as much for auditors as for engineers. In 2025, the U.S. Food and Drug Administration finalized ...

The revenue cycle keeps collecting promises. RPA was going to change everything. So was NLP. Then generative AI shifted the conversation entirely. Now it’s agentic AI, and the difference this time is ...

State Rep. Joe Tate, the first Black person to be speaker of the Michigan House of Representatives, will not seek re-election to his Detroit-based House seat in ...

Indian cricket has had many births and rebirths over the last five decades, an identity built on big unlikely results and a fighting spirit. The very peak of this came this week 25 years ago, when ...

Software testing has evolved significantly over the past decade. What began as heavily manual validation gradually shifted toward automation frameworks and continuous integration pipelines. Today, a ...